FDA panel recommends EUA for Moderna’s COVID-19 vaccine candidate

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 17 recommended the approval of Moderna’s mRNA-1273 COVID-19 vaccine candidate.

The panel voted 20-0, with one abstention, that FDA issue an emergency use authorization.

Once the EUA is issued by the FDA, which could happen as soon as today, Operation Warp Speed expects to begin shipping immediately to U.S. hospitals and other sites as designated by state and jurisdictional leaders. The vaccine is administered in two doses 28 days apart.